Publications by authors named "Valter Croci"

Claim this Profile
T
Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Simona Bindi, Daniele Fancelli, Cristina Alli, Daniela Berta, Jay A Bertrand, Valter Croci

Bioorg Med Chem· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
Maria Menichincheri, Clara Albanese, Cristina Alli, Dario Ballinari, Alberto Bargiotti, Valter Croci

J Med Chem· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
Italo Beria, Dario Ballinari, Jay Aaron Bertrand, Daniela Borghi, Roberto Tiberio Bossi, Valter Croci

J Med Chem· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Gabriella Traquandi, Marina Ciomei, Dario Ballinari, Elena Casale, Nicoletta Colombo, Valter Croci

J Med Chem· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
Maria Gabriella Brasca, Clara Albanese, Rachele Alzani, Raffaella Amici, Nilla Avanzi, Valter Croci

Bioorg Med Chem· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
Maria Gabriella Brasca, Nadia Amboldi, Dario Ballinari, Alexander Cameron, Elena Casale, Valter Croci

J Med Chem· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
Maria Menichincheri, Alberto Bargiotti, Jens Berthelsen, Jay A Bertrand, Roberto Bossi, Valter Croci

J Med Chem· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Alessia Montagnoli, Barbara Valsasina, Valter Croci, Maria Menichincheri, Sonia Rainoldi

Nat Chem Biol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
Patrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini, Paolo Cappella, Laura Gianellini, Valter Croci

Mol Cancer Ther· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of edotecarin in breast carcinoma models.
Marina Ciomei, Valter Croci, Fabio Stellari, Nadia Amboldi, Rosa Giavarini

Cancer Chemother Pharmacol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6-Substituted pyrrolo[3,4-c]pyrazoles: an improved class of CDK2 inhibitors.
Maria Gabriella Brasca, Clara Albanese, Raffaella Amici, Dario Ballinari, Luca Corti, Valter Croci

ChemMedChem· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
Chiara Soncini, Patrizia Carpinelli, Laura Gianellini, Daniele Fancelli, Paola Vianello, Valter Croci

Clin Cancer Res· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.
Marina Ciomei, Valter Croci, Antonella Ciavolella, Dario Ballinari, Enrico Pesenti

Clin Cancer Res· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
Monica Simeoni, Paolo Magni, Cristiano Cammia, Giuseppe De Nicolao, Valter Croci

Cancer Res· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis